Peter Gal MSc
Principal Health Economist
Prior to joining Visible Analytics, Peter was Senior Research Scientist in the Modelling and Simulation group of Evidera for 10 years. Prior to that, he worked in the financial services industry as a mathematical modeler for 12 years. At Morgan Stanley’s Market Risk Department his responsibilities included model reviews of derivative pricing and risk models. Prior to that, he worked at ING and Winterthur as a life insurance actuary.
In health economics Peter has global model development experience in the therapeutic areas of oncology, autoimmune conditions, kidney and liver disease, neurology, and visual disorders, including cost-effectiveness and budget impact models (partitioned survival, Markov cohort, microsimulation, discrete event simulation, and dynamic transition models). Peter worked in submissions for several health technology assessment agencies in the UK, Canada, France, Sweden. Peter was Evidera’s Best Practices Lead in modelling methodologies.
Peter published articles in health economic journals such as Pharmacoeconomics, Journal of Medical Economics, Journal of Market Access & Health, and Expert Review of Vaccines about economic models of non-alcoholic steatohepatitis (NASH), Covid-19, Parkinson's Disease, and non-small cell lung cancer, and presented posters about modelling methodology at the annual European ISPOR conferences since 2017.
Peter holds a BSc in programming and mathematics from the Eötvös Loránd University, Budapest, an MSc in economics with specialization in actuarial science and applied statistics from the Budapest University of Economic Sciences, and a diploma in quantitative finance from the Institute for Advanced Studies, Vienna, Austria.